Keyword Analysis & Research: pitavastatin pallabi

nih.gov

https://pubmed.ncbi.nlm.nih.gov/29666154/

WebPredictions were compared with previously reported plasma exposure changes of pitavastatin with these inhibitors. Although hepatic uptake inhibition of pitavastatin was 2 … Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub Publish Year: 2018

Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub

Publish Year: 2018

DA: 50 PA: 23 MOZ Rank: 60

aspetjournals.org

https://dmd.aspetjournals.org/content/dmd/early/2018/04/17/dmd.118.080614.full.pdf

WebApr 17, 2018 · MANUSCRIPT. Prediction and quantification of hepatic transporter-mediated uptake of pitavastatin. utilizing a combination of the Relative Activity Factor approach and … Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub Publish Year: 2018

Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub

Publish Year: 2018

DA: 86 PA: 4 MOZ Rank: 40

aspetjournals.org

https://dmd.aspetjournals.org/content/dmd/46/7/953.full.pdf

WebUptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modelings Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, … Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub Publish Year: 2018

Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub

Publish Year: 2018

DA: 77 PA: 28 MOZ Rank: 67

aspetjournals.org

https://dmd.aspetjournals.org/content/46/7/953

WebJul 1, 2018 · Predictions were compared with previously reported plasma exposure changes of pitavastatin with these inhibitors. Although hepatic … Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub Publish Year: 2018

Author: Pallabi Mitra, Samantha Weinheimer, Meeghan Michalewicz, Mitchell E Taub

Publish Year: 2018

DA: 64 PA: 63 MOZ Rank: 83

nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK557402/

WebJul 4, 2023 · Pitavastatin is a medication used in the management and treatment of hypercholesterolemia and dyslipidemia. It is in the statin … Published: 2023/07/04 pallabi

Published: 2023/07/04

pallabi

DA: 88 PA: 92 MOZ Rank: 6

springer.com

https://link.springer.com/article/10.1208/s12248-023-00882-7

WebJan 5, 2024 · The goal of this study is to use pitavastatin, a probe substrate of OATP1B transporters, as an example to investigate the predictivity of a human PBPK model by …

DA: 1 PA: 54 MOZ Rank: 63

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065553/

WebOct 22, 2010 · These data imply that pitavastatin is a stronger inhibitor of HMG-CoA reductase activity than any other statin, including rosuvastatin.38 Using the same … pallabi

pallabi

DA: 26 PA: 58 MOZ Rank: 33

clinicaltherapeutics.com

https://www.clinicaltherapeutics.com/article/S0149-2918(11)00503-0/fulltext

WebPitavastatin at doses of 1 to 4 mg/d was reported to be associated with reductions in LDL-C of 38% to 44% and in triglycerides of 14% to 22%, and with increases in HDL-C of 5% to 8% (all, P < 0.05). Overall, the effect of … pallabi

pallabi

DA: 77 PA: 66 MOZ Rank: 5

sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S0163782721000436

WebNov 1, 2021 · Pitavastatin is a unique lipophilic statin with a strong effect on lowering plasma total cholesterol and triacylglycerol. pallabi

pallabi

DA: 85 PA: 68 MOZ Rank: 35

nih.gov

https://pubmed.ncbi.nlm.nih.gov/22356292/

WebMar 5, 2012 · Pitavastatin (Livazo®, Livalo®), an inhibitor of HMG-CoA reductase (statin), is indicated for the reduction of elevated total cholesterol (TC) and low-density lipoprotein … pallabi

pallabi

DA: 95 PA: 12 MOZ Rank: 93